•
Jun 30, 2020
CRISPR Therapeutics Q2 2020 Earnings Report
CRISPR Therapeutics reported financial results for the second quarter ended June 30, 2020.
Key Takeaways
CRISPR Therapeutics reported a net loss of $79.7 million for the second quarter of 2020, with total collaboration revenue of less than $0.1 million. Cash and cash equivalents were $945.1 million as of June 30, 2020.
Dosing re-initiated in clinical trials of CTX001 for patients with severe hemoglobinopathies.
CTX001 received orphan drug designation from the U.S. FDA for sickle cell disease (SCD).
Expanded regenerative medicine portfolio through a collaboration with University Health Network (UHN), gaining access to hepatocytes.
Company expects to report data from its CTX001 program targeting hemoglobinopathies and its CTX110 program later this year.